Rapport Therapeutics, a clinical-stage biotech that was founded last year, raised $150 million in Series B financing, bringing its total funding to date to $250 million. The company's platform leverages receptor-associated proteins to create neurology drugs that have more focused activity in the brain, going after disease-driving circuits and cell types.
The DOJ has reportedly opened a criminal investigation into Cassava Sciences after allegations that the company s studies of an experimental Alzheimer s drug appeared to include altered images.